BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11779316)

  • 1. Primary malignant melanoma of the pharynx.
    Oztürk O; Ozek H; Cansiz H; Karakullukçu B
    J Laryngol Otol; 2001 Nov; 115(11):931-4. PubMed ID: 11779316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma.
    Proebstle TM; Scheibenbogen C; Sterry W; Keilholz U
    Eur J Cancer; 1996 Aug; 32A(9):1530-3. PubMed ID: 8911113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission of the liver metastases of anorectal malignant melanoma with regional chemotherapy: a case report.
    Köksal N; Müftüoglu T; Günerhan Y; Uskent N
    Hepatogastroenterology; 2000; 47(33):612-4. PubMed ID: 10918997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary malignant melanoma of the vagina.
    Baloglu A; Bezircioglu I; Cetinkaya B; Yavuzcan A
    Arch Gynecol Obstet; 2009 Nov; 280(5):819-22. PubMed ID: 19242707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
    Gibney GT; Atkins MB
    J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
    Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
    Recchia F; Candeloro G; Necozione S; Fumagalli L; Bratta M; Rea S
    Anticancer Drugs; 2008 Feb; 19(2):201-7. PubMed ID: 18176117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma.
    Schmittel A; Keilholz U; Max R; Thiel E; Scheibenbogen C
    Int J Cancer; 1999 Jan; 80(1):39-43. PubMed ID: 9935227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Our experience with interferon alpha: metastatic malignant melanoma.
    Merimsky O; Chaitchik S
    Mol Biother; 1992 Sep; 4(3):135-8. PubMed ID: 1445667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy.
    Savas B; Arslan G; Gelen T; Karpuzoglu G; Ozkaynak C
    Anticancer Res; 1999; 19(5C):4413-20. PubMed ID: 10650785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local control of primary oropharyngeal malignant melanomas with limited tissue excision: a report of three cases.
    Oztürk O; Cansiz H; Güzel MZ; Karakullukçu B; Ozek H
    Eur Arch Otorhinolaryngol; 2005 Feb; 262(2):89-92. PubMed ID: 15455245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
    Buzaid AC; Legha SS
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):23-8. PubMed ID: 7992096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
    Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.